| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
Guest Access | Sign In via User Name/Password
|
|
|
|||||||
Guest Access | Sign In via User Name/Password |
|||||||||
1 From the CALGB Statistical Center and Division of Biometry/Department of Community and Family Medicine, Duke University Medical Center, Durham, NC
2 From the Hollings Cancer Center, Medical University of South Carolina, Charleston
3 From the Division of Neoplastic Diseases, Mt Sinai Medical Center, New York
4 From the Department of Pathology, Brigham & Women's Hospital, Boston
5 From the Department of Pathology, Mt Sinai Medical Center, New York
6 From the Hematology/Oncology, University of Chicago Medical Center, Chicago
Purpose: To examine the individual and joint effect of various pretreatment clinical characteristics on the survival of patients with mesothelioma treated by the Cancer and Leukemia Group B (CALGB).
Patients and methods: Between June 1984 and September 1994, 337 patients with malignant mesothelioma and no prior chemotherapy were accrued to seven phase II studies conducted by the CALGB which screened the efficacy of 10 treatment regimens or dose levels. The eligibility criteria for all studies were virtually identical. Patient characteristics include the following: age older than 60 years (63%); male (83%); performance status (PS) of 0 or 1 (81%); chest pain (60%); definite asbestos exposure (62%); >5% weight loss (41%); and pleural involvement (94%). Median survival time (MST) for the 10 treatment regimens ranged from 3.9 to 9.8 months (overall=7.2; 95% confidence interval [CI], 6.5 to 8.3), with 1-year survival between 14% and 50% (overall=27%; 95% CI, 23 to 33%).
Results: Cox survival models and exponential regression trees were used to examine the prognostic importance of pretreatment patient characteristics. Univariate analyses show that patients with poor Eastern Cooperative Oncology Group PS, chest pain, dyspnea, platelet count (PLT) >400,000/µL, weight loss, serum lactate dehydrogenase (LDH) level >500 IU/L, pleural involvement, low hemoglobin (HGB) level, high WBC count, and increasing age over 75 years have a worse prognosis. With decreasing risk ratio, multivariate Cox analyses showed that pleural involvement, LDH >500 IU/L, poor PS, chest pain, PLT >400,000/µL, nonepithelial histology, and increasing age older than 75 years jointly predict poor survival. PS was the most important prognostic split in the regression tree. Terminal nodes were amalgamated to form six distinct prognostic subgroups with MST (2-year survival) of 13.9 (38%) in 36 patients, 9.5 (21%) in 36 patients, 9.2 (10%) in 146 patients, 6.5 (3%) in 33 patients, 4.4 (0%) in 73 patients, and 1.4 (0%) in 13 patients (p<0.0001).
Conclusions: The subgroup with the best survival (MST=13.9 months) included patients with PS=0 and age younger than 49 years, and patients with PS=0, age of 49 years or older, and HGB 
14.6. The worst survival (MST=1.4 months) occurred for patients with PS=1/2 and WBC 15.6/µL.
Key Words: mesothelioma • prognostic factor • survival
Submitted on November 26, 1996
Accepted on July 28, 1997
This article has been cited by other articles:
|
|
 |
|
  J. G. Edwards, A. E. Martin-Ucar, D. J. Stewart, and D. A. Waller Right extrapleural pneumonectomy for malignant mesothelioma via median sternotomy or thoracotomy?: Short- and long-term results Eur. J. Cardiothorac. Surg., May 1, 2007; 31(5): 759 - 764. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E. E. Vokes, M. C. Perry, H. L. Kindler, and M. R. Green The cancer and leukemia group B respiratory committee. Clin. Cancer Res., June 1, 2006; 12(11): 3581s - 3588s. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Govindan, R. A. Kratzke, J. E. Herndon II, G. A. Niehans, R. Vollmer, D. Watson, M. R. Green, H. L. Kindler, and on behalf of the Cancer and Leukemia Group B Gefitinib in Patients with Malignant Mesothelioma: A Phase II Study by the Cancer and Leukemia Group B Clin. Cancer Res., March 15, 2005; 11(6): 2300 - 2304. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. A. Fennell, A. Parmar, J. Shamash, M. T. Evans, M. T. Sheaff, R. Sylvester, K. Dhaliwal, N. Gower, J. Steele, and R. Rudd Statistical Validation of the EORTC Prognostic Model for Malignant Pleural Mesothelioma Based on Three Consecutive Phase II Trials J. Clin. Oncol., January 1, 2005; 23(1): 184 - 189. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Nici, B. Monfils, and P. Calabresi The Effects of Taurolidine, a Novel Antineoplastic Agent, on Human Malignant Mesothelioma Clin. Cancer Res., November 15, 2004; 10(22): 7655 - 7661. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Vogelzang In Reply: J. Clin. Oncol., October 15, 2004; 22(20): 4235 - 4236. [Full Text] [PDF]
|
|
|
|
 |
|
 F. Ebstein, C. Sapede, P.-J. Royer, M. Marcq, C. Ligeza-Poisson, I. Barbieux, L. Cellerin, G. Dabouis, and M. Gregoire Cytotoxic T Cell Responses against Mesothelioma by Apoptotic Cell-pulsed Dendritic Cells Am. J. Respir. Crit. Care Med., June 15, 2004; 169(12): 1322 - 1330. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
N. J. Vogelzang, J. J. Rusthoven, J. Symanowski, C. Denham, E. Kaukel, P. Ruffie, U. Gatzemeier, M. Boyer, S. Emri, C. Manegold, et al. Phase III Study of Pemetrexed in Combination With Cisplatin Versus Cisplatin Alone in Patients With Malignant Pleural Mesothelioma J. Clin. Oncol., July 15, 2003; 21(14): 2636 - 2644. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. H. Schouwink, L. Schultze Kool, E. J. Rutgers, F. A. N. Zoetmulder, N. van Zandwijk, M. J. v.d. Vijver, and P. Baas The value of chest computer tomography and cervical mediastinoscopy in the preoperative assessment of patients with malignant pleural mesothelioma Ann. Thorac. Surg., June 1, 2003; 75(6): 1715 - 1718. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 I. Monnet, J.-L. Breau, D. Moro, H. Lena, J.-C. Eymard, O. Menard, J.-P. Vuillez, M. Chokri, J.-L. Romet-Lemonne, and M. Lopez Intrapleural Infusion of Activated Macrophages and {gamma}-Interferon in Malignant Pleural Mesothelioma* : A Phase II Study Chest, June 1, 2002; 121(6): 1921 - 1927. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. G. Edwards, S. P. Faux, S. M. Plummer, K. R. Abrams, R. A. Walker, D. A. Waller, and K. J. O'Byrne Cyclooxygenase-2 Expression Is a Novel Prognostic Factor in Malignant Mesothelioma Clin. Cancer Res., June 1, 2002; 8(6): 1857 - 1862. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. M. Mikulski, J. J. Costanzi, N. J. Vogelzang, S. McCachren, R. N. Taub, H. Chun, A. Mittelman, T. Panella, C. Puccio, R. Fine, et al. Phase II Trial of a Single Weekly Intravenous Dose of Ranpirnase in Patients With Unresectable Malignant Mesothelioma J. Clin. Oncol., January 1, 2002; 20(1): 274 - 281. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J G Edwards, K R Abrams, J N Leverment, T J Spyt, D A Waller, and K J O'Byrne Prognostic factors for malignant mesothelioma in 142 patients: validation of CALGB and EORTC prognostic scoring systems Thorax, September 1, 2000; 55(9): 731 - 735. [Abstract] [Full Text]
|
|
|
|
|
|
J P C STEELE and R M RUDD Malignant mesothelioma: predictors of prognosis and clinical trials Thorax, September 1, 2000; 55(9): 725a - 726. [Full Text]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |
